Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
124
Glycosaminoglycans01:23

Glycosaminoglycans

4.8K
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
4.8K
T Cell Types and Functions01:24

T Cell Types and Functions

966
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
966
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Clinico-epidemiological Profile of Facial Dermatoses at a Teaching Hospital in Eastern India.

Annals of African medicine·2026
Same author

Omalizumab: a broader role in dermatology? Evidence and the road ahead.

Italian journal of dermatology and venereology·2025
Same author

Revisiting risankizumab: a newer biologic drug in dermatology.

Italian journal of dermatology and venereology·2024
Same author

Comparison of the clinical efficacy of topical tretinoin 0.05% cream and tacrolimus 0.1% ointment plus iontophoresis in the management of palmoplantar psoriasis.

Clinical and experimental dermatology·2024
Same author

Saxophone penis: A sequel to penoscrotal hidradenitis suppurativa.

Indian journal of sexually transmitted diseases and AIDS·2023
Same author

Giant Solitary Trichoepithelioma: A Diagnosis of Exclusion.

International journal of trichology·2023
Same journal

Negative Maple Leaf-Like Areas are More Visible in Sub-UV Dermatoscopy - Further Applications and New Perspectives.

Dermatology practical & conceptual·2026
Same journal

Comparative Study on the Therapeutic Efficacy of Topical Bimatoprost (0.03%) Ophthalmic Solution and Tacrolimus (0.1%) Ointment in Stable Vitiligo.

Dermatology practical & conceptual·2026
Same journal

Dermatological Indicators of Systemic Autoimmune Disease: Clinical Links to Ocular Involvement.

Dermatology practical & conceptual·2026
Same journal

Amelanotic Melanoma Presenting As a Scaly Plaque.

Dermatology practical & conceptual·2026
Same journal

Correction.

Dermatology practical & conceptual·2026
Same journal

Applying RCM-Based Criteria to LC-OCT for Classifying Mucosal Melanoses: A Proof-of-Concept Study.

Dermatology practical & conceptual·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Guselkumab - In Psoriasis and Beyond.

Aditya Kumar Bubna1, Vinayak Viplav1

  • 1Department of Dermatology, Katihar Medical College, Karim Bagh, Katihar, Bihar, India.

Dermatology Practical & Conceptual
|August 9, 2024
PubMed
Summary
This summary is machine-generated.

Guselkumab, an interleukin-23p19 inhibitor, effectively treats psoriasis and shows promise for other skin conditions, including rare cancers like Stewart-Treves angiosarcoma, with a good safety profile.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

924

Related Experiment Videos

Last Updated: Jun 17, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

924

Area of Science:

  • Dermatology
  • Immunology
  • Oncology

Background:

  • Guselkumab is the first approved interleukin-23p19 inhibitor for moderate to severe psoriasis.
  • Its therapeutic value extends beyond psoriasis to various dermatologic conditions.

Purpose of the Study:

  • To review the efficacy of guselkumab in psoriasis management.
  • To explore its applications in off-label dermatologic disorders.

Main Methods:

  • A narrative review of studies was conducted.
  • Literature search performed on PubMed, Google Scholar, Scopus, and ResearchGate.
  • Keywords used: "Guselkumab", "Psoriasis", and "other dermatological disorders".

Main Results:

  • Guselkumab is effective for psoriasis and psoriatic arthropathy.
  • Successful use in hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, and pyoderma gangrenosum.
  • Emerging utility in Stewart-Treves angiosarcoma (STA).

Conclusions:

  • Guselkumab's benefits encompass numerous dermatologic conditions beyond psoriasis.
  • Potential applications in oncology, particularly for STA, warrant further investigation.
  • Guselkumab demonstrates an acceptable safety profile.